Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort

REFERENCES

1. 1.↵
   1. Gladman DD,
   2. Antoni C,
   3. Mease P,
   4. Clegg DO,
   5. Nash P

   . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14–7.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. McHugh NJ,
   2. Balachrishnan C,
   3. Jones SM

   . Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003;42:778–83.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Gordon GB,
   2. Ruderman E

   1. Gladman DD

   . Disability and quality of life considerations. Psoriatic arthritis. In: Gordon GB, Ruderman E, eds. Psoriasis and psoriatic arthritis: an integral approach. Heidelberg: Springer-Verlag; 2005:118–237.
4. 4.↵
   1. Helliwell P,
   2. Coates L,
   3. Chandran V,
   4. Gladman D,
   5. de Wit M,
   6. FitzGerald O,
   7. et al.

   Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res 2014;66:1759–66.

   OpenUrlCrossRef
5. 5.↵
   1. Perrotta FM,
   2. Lubrano E

   . Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study. Postgrad Med 2016;128:693–6.

   OpenUrl
6. 6.↵
   1. Ash Z,
   2. Gaujoux-Viala C,
   3. Gossec L,
   4. Hensor EM,
   5. FitzGerald O,
   6. Winthrop K,
   7. et al.

   A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319–26.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Glintborg B,
   2. Østergaard M,
   3. Dreyer L,
   4. Krogh NS,
   5. Tarp U,
   6. Hansen MS,
   7. et al.

   Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382–90.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Perrotta FM,
   2. Marchesoni A,
   3. Lubrano E

   . Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 2016;43:350–5.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Lubrano E,
   2. Parsons WJ,
   3. Perrotta FM

   . Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol 2016;43:918–23.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Lubrano E,
    2. Perrotta FM

    . Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag 2016;12:1587–92.

    OpenUrl
11. 11.↵
    1. Perrotta FM,
    2. Lubrano E

    . New approved drugs for psoriatic arthritis. Reumatismo 2016;68:57–64.

    OpenUrl
12. 12.↵
    1. Lubrano E,
    2. Perrotta FM

    . Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis. Drugs 2016;76:663–73.

    OpenUrl
13. 13.↵
    1. Coates LC,
    2. Kavanaugh A,
    3. Mease PJ,
    4. Soriano ER,
    5. Laura Acosta-Felquer M,
    6. Armstrong AW,
    7. et al.

    Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016;68:1060–71.

    OpenUrl
14. 14.↵
    1. Gossec L,
    2. Smolen JS,
    3. Ramiro S,
    4. de Wit M,
    5. Cutolo M,
    6. Dougados M,
    7. et al.

    European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499–510.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Lubrano E,
    2. Soriano E,
    3. FitzGerald O

    . Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol 2013;31 Suppl 78:S54–8

    OpenUrlPubMed
16. 16.↵
    1. Lubrano E,
    2. Perrotta FM,
    3. Kavanaugh A

    . An overview of low disease activity and remission in psoriatic arthritis. Clin Exp Rheumatol 2015;33 Suppl 93:51–4.

    OpenUrl
17. 17.↵
    1. Coates LC,
    2. Fransen J,
    3. Helliwell PS

    . Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48–53.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Coates L,
    2. Helliwell P

    . Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Car Res 2010;62;965–9.

    OpenUrl
19. 19.↵
    1. Coates LC,
    2. Helliwell PS

    . Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 2016;43:371–5.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Helliwell PS,
    2. FitzGerald O,
    3. Fransen J,
    4. Gladman DD,
    5. Kreuger GG,
    6. Callis-Duffin K,
    7. et al.

    The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986–91.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Helliwell PS,
    2. FitzGerald O,
    3. Fransen J

    . Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol 2014;41:1212–7.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Schoels MM,
    2. Aletaha D,
    3. Alasti F,
    4. Smolen JS

    . Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811–8.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Soriano ER

    . The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis. J Rheumatol 2012;89:67–70.

    OpenUrl
24. 24.↵
    1. Taylor W,
    2. Gladman D,
    3. Helliwell P,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H;
    7. CASPAR Study Group

    . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Healy PJ,
    2. Helliwell PS

    . Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686–91.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Chandran V,
    2. Gottlieb A,
    3. Cook RJ,
    4. Duffin KC,
    5. Garg A,
    6. Helliwell P,
    7. et al.

    International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2009;61:1235–42.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Ranza R,
    2. Marchesoni A,
    3. Calori G,
    4. Bianchi G,
    5. Braga M,
    6. Canazza S,
    7. et al.

    The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 1993;11:123–8.

    OpenUrlPubMed
28. 28.↵
    1. Ware JE Jr,
    2. Sherbourne CD

    . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Cauli A,
    2. Gladman DD,
    3. Mathieu A,
    4. Olivieri I,
    5. Porru G,
    6. Tak PP,
    7. et al;
    8. GRAPPA 3PPsA Study Group

    . Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011;38:898–903.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Nell-Duxneuner VP,
    2. Stamm TA,
    3. Machold KP,
    4. Pflugbeil S,
    5. Aletaha D,
    6. Smolen JS

    . Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010;69:546–9.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Lubrano E,
    2. Perrotta FM,
    3. Marchesoni A,
    4. D’Angelo S,
    5. Ramonda R,
    6. Addimanda O,
    7. et al.

    Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol 2015;42:258–63.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Spadaro A,
    2. Lubrano E,
    3. Marchesoni A,
    4. D’Angelo S,
    5. Ramonda R,
    6. Addimanda O,
    7. et al.

    Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology 2013;52:1914–9.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Haddad A,
    2. Thavaneswaran A,
    3. Ruiz-Arruza I,
    4. Pellett F,
    5. Chandran V,
    6. Cook RJ,
    7. et al.

    Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res 2015;67:842–7.

    OpenUrlCrossRef
34. 34.↵
    1. Coates LC,
    2. Helliwell PS

    . Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol 2016;43:356–61.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Sheane BJ,
    2. Thavaneswaran A,
    3. Gladman DD,
    4. Chandran V

    . Attainment of minimal disease activity using methotrexate in psoriatic arthritis. J Rheumatol 2016;43:1718–23.

    OpenUrlAbstract/FREE Full Text